DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O].
Fathallah
Hassana
H
D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors; D019175:DNA Methylation / Q000187:drug effects*; D000077209:Decitabine; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D005319:Fetal Hemoglobin / Q000378:metabolism; D051548:Histone Acetyltransferases / Q000037:antagonists & inhibitors; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology / Q000627:therapeutic use; D017086:beta-Thalassemia / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D000077209:Decitabine; D005319:Fetal Hemoglobin; D004248:DNA (Cytosine-5-)-Methyltransferases; D051548:Histone Acetyltransferases; D001374:Azacitidine; D006918:Hydroxyurea